Screener
Talphera, Inc. TLPH Q3 2026 earnings
Reported November 12, 2026 · After market close
Revenue-
EPS-$0.05In line
EPS estimate-$0.05
“We believe nafamostat has the potential to address an important unmet need as a regional anticoagulant for critically ill patients undergoing CRRT. Our updated market research, including physician feedback on nafamostat compared with currently used products, supports its potential adoption in CRRT and an increased peak sales estimate of more than $200 million.”
Next report
Date not yet announcedFinancials
Q3 2026Valuation & ratios
Segments
By segment
Versus estimates
Revenue
FAQ
- When did Talphera, Inc. report Q3 2026 earnings?
- Talphera, Inc. (TLPH) reported Q3 2026 earnings on November 12, 2026 after market close.
- What were Talphera, Inc.'s Q3 2026 revenue and EPS?
- Talphera, Inc. reported revenue of - and eps of $-0.05 for Q3 2026.
- Did Talphera, Inc. beat estimates in Q3 2026?
- EPS beat the consensus estimate of $-0.05 by $0.00.
- How did Talphera, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 100.0% from $1.0K a year earlier and eps grew 54.5% from $-0.11.
- Where can I find Talphera, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001437749-26-036555) and the 10-Q periodic report (0001437749-26-036598) directly on SEC EDGAR. The filing index links above go to sec.gov.
